Phase I/IIb Study of the Tumor Targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With the Anti-PD1 Antibody Nivolumab in Patients With Non-small Cell Lung Cancer
Latest Information Update: 26 Jul 2022
At a glance
- Drugs F16 IL2 fusion protein (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms Nivokin
- Sponsors Philogen
Most Recent Events
- 26 Jul 2022 New trial record